It seems that every day brings a new story about the hugely popular diabetes and weight loss drugs like Ozempic and Wegovy. Both of these medications are just different forms of a molecule called semaglutide, which mimics a gut peptide that our bodies make naturally after we eat. We know semaglutide helps people lose interest in food, but what if it were just as effective at reducing interest in alcohol? And what about other drugs? And could there be a darker side to these benefits? Join Dr. Kyle Simmons and OSU Vice President Kenneth Sewell for an interview and audience Q&A to talk about a novel pharmaco-imaging clinical trial happening at OSU examining whether semaglutide might provide a transformational new treatment for patients struggling with addiction.